About Isofol

Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with new dosage regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Read more >>

Upcoming Events

  • February 19, 2025 - February 19, 2025
    Year-end report 2024
  • April 09, 2025 - April 11, 2025
    Annual report 2024, published in week 15, April 2025
  • May 21, 2025 - May 21, 2025
    Interim report January-March 2025

FOLLOW US

Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top